Roth Capital Reiterates Buy On Prosensa As It Begins NDA Submission For Drisapersen
In a research report issued Monday, Roth Capital analyst Debjit Chattopadhyay reiterated coverage with a Buy rating on Prosensa Holding (NASDAQ:RNA) and a price target of $17, as the company announced the initiation of a rolling NDA submission for drisapersen for treating Duchenne muscular dystrophy (DMD).
Chattopadhyay noted, “The rolling NDA submission was made possible by its breakthrough therapy designation among others. We anticipate that the FDA will convene an advisory panel meeting during 1H15 and potentially grant accelerated approval during 2H15. With multiple clinical and regulatory milestones, and a wide EV disparity, we recommend owning Prosensa at current levels.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -17.7% and a 17.1% success rate. Chattopadhyay has a -5.3% average return when recommending RNA, and is ranked #3303 out of 3324 analysts.